GlynnTech

GlynnTech is a clinical-stage biotechnology company specializing in glycoscience and glyco-engineering to develop next-generation biologics. The company utilizes its proprietary chemoenzymatic glycan synthesis (CGS) platform to create glyco-optimized antibodies and vaccines with improved therapeutic profiles. By precisely controlling glycan structures, GlynnTech aims to enhance the efficacy and safety of treatments for oncology and infectious diseases. In addition to its internal drug discovery efforts, the company operates as a specialized CRO, providing advanced glycan analysis and characterization services to global pharmaceutical partners. Headquartered in Beijing with facilities in Suzhou, GlynnTech is led by a team of experts dedicated to advancing the field of glycobiology.